Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect
2024-517115-70-00Phase 2Authorised
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban, clopidogrel and aspirin in patent foramen ovale (PFO) and atrial septal defect (ASD) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Hemostatic endpoints (coagulation and platelet activation biomarkers). Planned start Aug 2024; status: authorised.
02
Drugs
rivaroxabanclopidogrelaspirin
03
Conditions
patent foramen ovale (PFO)atrial septal defect (ASD)
Beyond the preview
Go deeper on 2024-517115-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517115-70-00.